Hi Neil,
No, nothing about next step in those press releases but Dr Silverman and Dr Holland at Mount Sinai School of Medicine have a patent application called AZACYTIDINE ANALOGUES AND USES THEREOF dated 08-20-2009.
They write
:"...The cytotoxic activity of 5-Aza-C-5'-elaidic acid was not only maintained but increased 50-fold when the hENT1 and hENT2 nucleoside transporters were blocked by the use of dipyridamole. The increased activity in cells where the nucleoside transporters are blocked by dipyridamole is surprising, and may indicate even higher activity in patients with resistance to treatment caused by lack of nucleoside transporters."
They seem to look at both Vidaza and Dacogen.
http://www.faqs.org/patents/app/20090209482
Kind regards
Birgitta-A